Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Rusfertide in Polycythemia Vera Requiring Phlebotomy
2023-509750-58-00Phase 3Authorised
- Sponsor
- Takeda
- Start
- Apr 2024
- Modality
- Peptides
- Countries
- 20
01
Overview
Phase 3, randomised, double-blind trial in polycythemia vera (PV) comparing Rusfertide with Placebo (2 arms). Primary endpoint: Primary response rate (Week 20–32). Planned start Apr 2024; status: authorised.
02
Drugs
rusfertide
03
Conditions
polycythemia vera (PV)
Beyond the preview
Go deeper on 2023-509750-58-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509750-58-00.